- Title:
- Digital Health Innovations for Screening and Mitigating Mental Health
- - ã¿ã¤ãã«ï¼æ¥æ¬ã®æ°å ¥ç大å¦çã«ãããçºéé害å¦çã®é »åº¦ã¨ã¡ã³ã¿ã«ãã«ã¹ç¶æ ï¼æ¨ªæç調æ»
- ã¿ã¤ãã«: ADHDã®åä¾ã«ãããæè¦å¦çãå®è¡æ©è½ãããã³è¡å
- ã¿ã¤ãã«ï¼å¦è¡ç²¾ç¥å»å¦ã¯èª°ã®ä»äºã«ãé¢ä¿ãã¦ãã¾ãã
- Developmental trajectories in infants and pre-school children with
- ã¿ã¤ãã«: èªéçã¹ãã¯ãã©ã é害ã«ãããä¸æã®éºä¼çµè·¯ã®ç¹å¾´ä»ã
- Factors Associated with Mental Health Service Use Among Children with
- - ã¿ã¤ãã«: å°å ããªã³ãã£ãããã¢ã«ãããç²¾ç¥ç¾æ£ã®åä½µçï¼å¤æ½è¨ã³ãã¼ãç 究
- Neonatal Survival and Outcomes following Periviable Rupture of Membranes
- Sleep problems among Asian preschool children with neurodevelopmental
- ãæ¯è¦ªã®å¨ç£æãã¤ç ã¨ADHDçç¶ã®ãªã¹ã¯ï¼ã·ã¹ãããã£ãã¯ã¬ãã¥ã¼ããã³ã¡ã¿åæã«ãã観å¯ã
- ã¿ã¤ãã«ï¼ãããåå¿åãå©ç¨ããæ£è ã®ä½ç½®æ¤åºã«ãã褥ç¡äºé²ã¨ç®¡ç
- ã¿ã¤ãã«ï¼ãã¯ãªã¨ã¤ãã£ãèªèçè«:注ææ¬ å¦å¤åæ§é害ã«ãããæ¬è³ªçãªèªå·±èª¿æ´ã®ã°ã©ã¦ã³ãã£ã³ã°çè«ç 究
- ã¿ã¤ãã«: ã¸ã«ã»ãã»ã©ã»ãã¥ã¬ããçå群æ£è ã«ãããéãããã¤ã§ç¤¾ä¼çã«ä¸é©åãªè¡å
- ã¿ã¤ãã«: ADHDã®è¬ç©ãå°å ã³ãã¼ãç 究ã§ã®èº«é·ã¨ä½éã«åã¼ãæ½å¨çå½±é¿ãLIFE Child Studyã«ããã
- è«æã¿ã¤ãã«: ADHDã®éºä¼çç æ ãæããã«ããè³çµç¹ã®è»¢åã¨DNAã¡ãã«åã®ãã«ããªãã¯ã¹ç 究ã
- Health care costs of incident ADHD in children and adolescents in
- Psychometric evaluation of the Clinical Interview for Externalizing
Title:
COVID-19ã¯ã¯ãã³ã«å¯¾ãã親ã®æåã¨æçå¿ï¼ç²¾ç¥ããã³è¡åé害ãæã¤åä¾ã®ä¸¡è¦ªã対象ã¨ããç 究
è¦ç´:
- COVID-19ãã³ãããã¯ä¸ã«ç¹ã«éè¦æ§ãå¢ãPVHã調æ»
- ADHDãä¸å®é害ãè¡åé害ãªã©ãæ§ã ãªç²¾ç¥ç¥çµçºéé害ãæã¤åä¾ã®ä¸¡è¦ªã対象ã«å®æ½
- 5-11æ³ã®ç²¾ç¥ããã³è¡åé害ãæã¤åä¾ã®ä¸¡è¦ªã¨å¥å¸¸å ã®ä¸¡è¦ªã対象
- ç²¾ç¥é害ãæã¤åä¾ã®ä¸¡è¦ªã«ãããã¯ã¯ãã³æçã¯æ¨æºãä¸åã
- æè²æ°´æºã¨ã¯ã¯ãã³æçã¯COVID-19ã¯ã¯ãã³æ¥ç¨®æåã«å½±é¿
- ç²¾ç¥å»çé¢ä¿è ã«ããåå¥ä»å ¥ãéè¦ã§ãåä¾ã®ããã®ææåä¸ã«è²¢ç®
Digital Health Innovations for Screening and Mitigating Mental Health
Impacts of Adverse Childhood Experiences: Narrative Review.
- å¹¼å°æã«ãããæªãçµé¨ã¨è¯ãçµé¨ã®ä¸¡æ¹ã«ããããããã¨ã¯ãå人ã®ç涯ãéãã¦å¿èè¡ç®¡ãå ç«ã代è¬ãç¥çµæ©è½ã«å½±é¿ãä¸ãããã¨ã証æããã¦ããã
- æªãå¹¼å°æã®çµé¨ï¼ACEsï¼ã¯ãå¥åº·ã¨å¹¸ç¦ã«æ·±å»ãªå½±é¿ãåã¼ãå¯è½æ§ããããæ人æã«ãåã¶ã
- ãã®ç 究ã¯ãå¹¼å ãè¥è ã®ACEsã«é¢é£ãããªã¹ã¯ãç²¾ç¥çå¥åº·ä¸ã®å½±é¿ãã¹ã¯ãªã¼ãã³ã°ã軽æ¸ããããã«ãã¸ã¿ã«ãã«ã¹ãã¯ããã¸ã¼ï¼DHTsï¼ã¨äººå·¥ç¥è½ã使ç¨ããæ¹æ³ã«ã¤ãã¦ã®èª¬æçã¬ãã¥ã¼ãæä¾ãã¦ããã
- æ°å¤ãã®ãã¼ã¿ãã¼ã¹ãã2017å¹´8æãã2022å¹´8æã¾ã§ã«çºè¡¨ãããç 究ãæ¤ç´¢ãããã¸ã¿ã«ãã«ã¹ä»å ¥ã¨å¹¼å°æããã³éå°å¹´æã®ç²¾ç¥çå¥åº·ã«é¢é£ããè² ã®å¥åº·ææã®è»½æ¸ãããã³å¹¼å°æããã³éå°å¹´æã®ç²¾ç¥ç¾æ£ã«é¢é£ããACEçºçã®äºé²ãæ¢ã£ãã
- æ¤ç´¢çµæãããDHTã®çµã¿è¾¼ã¿ã¯ãæåè£ã«å°å ¥ãããã°ãä¸å©ã¾ãã¯ãã©ã¦ãçãªåºæ¥äºã«ãããåä¾æ代ã®ç²¾ç¥çå¥åº·å¾éºçãPTSDãèªæ®ºè¡åãæç´¢ãä¸å®ããã¤ç ã注ææ¬ é¥ã»å¤åæ§é害ãå«ãç¾æ£ã®ç®¡çã«é¢é£ããé¢é£ããã±ã¢æä¾ã®è³ªãåä¸ãããå¯è½æ§ããããã¨ã示åãããã
- DHTãæ©æ¢°å¦ç¿ãã¼ã«ãèªç¶è¨èªå¦çã人工ç¥è½ã®ä½¿ç¨ã¯ãACEsã¨é¢é£ãããªã¹ã¯è¦å ã軽æ¸ããã®ã«å½¹ç«ã¤å¯è½æ§ããããæ³çè¦å¶ãã»ãã¥ãªãã£ããã©ã¤ãã·ã¼ãããã³æ©å¯ä¿è¨¼ã®ä¸ããã¸ã¿ã«ãã¯ããã¸ã¼ã¯ãåä¾ãè¥è ã®å¥å ¨ãªæé·ãä¿é²ããã¬ã¸ãªã¨ã³ã¹ãé«ããå¿ è¦ã¨ãã人ã ã«ä¿¡é ¼ã§ããå ¬è¡è¡çè³æºãæä¾ããã®ã«å½¹ç«ã¤ãã¨ãã§ããã
- ã¿ã¤ãã«ï¼æ¥æ¬ã®æ°å ¥ç大å¦çã«ãããçºéé害å¦çã®é »åº¦ã¨ã¡ã³ã¿ã«ãã«ã¹ç¶æ ï¼æ¨ªæç調æ»
- è¦ç´ï¼çºéé害ãæã¤å¦çã¯ãé«æ ¡ãã大å¦ã¸ã®ç§»è¡æã«ç°å¢ã®å¤åã«ä¸å®ãæãã¦ãã¾ããæ¬ç 究ã¯ãæ°å ¥ç大å¦çã®ä¸ã§ã®èªéçã¹ãã¯ãã©ã é害ï¼ASDï¼ã¨æ³¨ææ¬ é¥ï¼å¤åæ§é害ï¼ADHDï¼ã®é »åº¦ãããã³å ¥å¦å¾ã®ã¡ã³ã¿ã«ãã«ã¹ãªã¹ã¯ã調æ»ãã¾ããã横æç調æ»ãè¡ããASDã¨ADHDã®é »åº¦ã示ãããã«èªéçã¹ãã¯ãã©ã ææ°ï¼AQï¼ããã³æ人ADHDãã¹ãï¼A-ADHDï¼ã使ç¨ãã¾ãããã¾ããå½¼ãã®ã¡ã³ã¿ã«ãã«ã¹ç¶æ ãè©ä¾¡ããããã«ã«ã¦ã³ã»ãªã³ã°ã»ã³ã¿ã¼å¿ççç¶è©ä¾¡ï¼CCAPSï¼-æ¥æ¬èªã使ç¨ãã¾ãããçµæãããæ°å ¥ç大å¦çã®ä¸ã§ASDã¨ADHDã®ç¹å¾´ãè¦ãããã®ã¯8.58%ã§ããããããã®å¦çã¯å¤§å¦ã«å ¥å¦ããéã«ã¡ã³ã¿ã«ãã«ã¹åé¡ã®é«ããªã¹ã¯ãæã£ã¦ãããã¨ãæããã¨ãªãã¾ããã
ã¿ã¤ãã«: ADHDã®åä¾ã«ãããæè¦å¦çãå®è¡æ©è½ãããã³è¡å
è¦ç´:
- ADHDã®åä¾ã«ããã¦ã¯ãæè¦å¦çãå®è¡æ©è½ãããã³è¡åã®é¢é£æ§ã¯æ確ã§ã¯ãªã
- ãã®ç 究ã®ç®çã¯ãADHDã®åä¾ã«ããã¦æè¦å¦çã¨è¡åã®é¢ä¿ã«ãããå®è¡æ©è½ã®ä¸éçå½¹å²ã調æ»ãããã¨ã§ãã£ã
- 63人ã®åä¾ï¼51人ã®ç·ã®åï¼ã7~14æ³ãåå ãä»è·è ã«ãã£ã¦æè¦ãããã¡ã¤ã«2ï¼SP-2ï¼ãå®è¡æ©è½è©ä¾¡å°ºåº¦2ï¼BRIEF-2ï¼ãå ç«¥è¡åãã§ãã¯ãªã¹ãï¼CBCLï¼ãè¨å ¥ããã
- æè¦å¦çãå®è¡æ©è½ãããã³è¡åã®éã«ã¯ãæ£ã®ãã¤ææãªé¢é£ãè¦ããã
- ããã«ãæè¦å¦çã¨è¡åã®éã«ã¯ãå®è¡æ©è½ã«ãã£ã¦ä¸éçãªå½±é¿ããããæè¦å¦çã¨è¡åã®é¢ä¿ã調ç¯ãã¦ãããã¨ã示åããã
- ãããã®çµæã¯ãä»ã®ç¥çµçºéé害ã«é¢ããã¨ããã³ã¹ã«ä»å 価å¤ãæä¾ããæè¦å¦çãå®è¡æ©è½ã«é¢é£ããåºæ¬çå´é¢ã§ããå¯è½æ§ãããããããADHDã«ããã¦è¡åã«å½±é¿ãä¸ãããã¨ã示åãã¦ãã
ã¿ã¤ãã«ï¼å¦è¡ç²¾ç¥å»å¦ã¯èª°ã®ä»äºã«ãé¢ä¿ãã¦ãã¾ãã
è¦ç´ï¼
- å¦è¡ç²¾ç¥å»å¦ã®ä¾¡å¤ã¨æ§è³ªãèãã
- ãã®å°éã¨ç²¾ç¥ç§å»ãå¦è ã¨ãã¦ã©ãå®ç¾©ãããããå°ãã
- å¦è¡ç²¾ç¥å»å¦ãè¨åºãµã¼ãã¹ã«å©çãããããèãæ¹ã¨æãã
- 次ä¸ä»£ã®å¦è ãã©ããã£ã¦é¼èãããã«ã¤ãã¦è°è«ãã
Developmental trajectories in infants and pre-school children with
Neurofibromatosis 1.
- NF1 children exhibit cognitive, behavioral, and social differences
compared to typically developing children, but the timing and sequence
of these differences are not well understood.
- This study followed NF1 and typically developing children from
infancy to preschool age to examine cognitive, behavioral, ADHD trait,
and autism symptom development.
- Cognitive and behavioral skills development differed significantly
between NF1 and typically developing children, with NF1 children
scoring lower at 24 months.
- NF1 children showed higher levels of autism and ADHD traits at 24
months, and 14% met autism criteria at 36 months.
- Limitations include a small sample size, use of online assessments
due to the COVID-19 pandemic, and potential inaccuracies in autism
trait assessment.
- By 24 months, NF1 children already exhibit lower cognitive skills,
adaptive behavior, and higher levels of autism and ADHD traits
compared to typically developing children.
ãããã®è¦ç¹ãã¾ã¨ããã¨ãNF1ï¼ç¥çµç·ç¶è «ç1åï¼ã®å¹¼å ãå°±å¦åå ç«¥ã®çºéè»è·¡ã示ãç 究ã§ãNF1ã«ããã¦ä½ãèªç¥è½åãé©å¿è¡åãé«ãèªéçããã³ADHDç¹æ§ãæ©ãææããè¦ããããã¨ã示ããããCOVID-19ã®å½±é¿ãå°è¦æ¨¡ãªãµã³ãã«ãµã¤ãºãªã©ã®å¶éãããããNF1ã®åã©ããã¡ã®æ©æã®çºéã¢ãã¿ãªã³ã°ãé©åãªæ©æä»å ¥ã¸ã®è¨åãéè¦ã§ããã¨çµè«ãããã
ã¿ã¤ãã«: èªéçã¹ãã¯ãã©ã é害ã«ãããä¸æã®éºä¼çµè·¯ã®ç¹å¾´ä»ã
- èæ¯
- èªéçã¹ãã¯ãã©ã é害ï¼ASDï¼ã¯éå ¸åçãªç¤¾ä¼æ©è½ãã¿ã¼ã³ãç¹°ãè¿ã/å¶éãããè¡åãç¹å¾´ã®ç¥çµçºéç¾æ£ã§ãããASDã¯ADHDã¨å ±åãããã¨ãä¸è¬çã§ãããè¨åºçãªç¬ç«æ§ã«ããããããã両è ã¯ããªãã®éºä¼çéãªããæã¤ãå ±éã®éºä¼ç責任ãèããã¨ãADHDã¨ç¬ç«ãã¦ASDã®çºçãªã¹ã¯ãå¢å ãããéºä¼çµè·¯ã¯ä¸æã§ããã
- æ¹æ³
- ASDã¨ADHDã®GWASãµããªã¼çµ±è¨ãGenomic Structural Equation
Modelingï¼SEMï¼ã«é©ç¨ããASDã®éºä¼çåæ£ãASDåºæã®ãã®ï¼uASDï¼ã¨ADHDã¨å
±æãããã®ã«å解ãããuASDã¨83ã®å¤é¨ãã¬ã¤ãã¨ã®éºä¼çç¸é¢ãè¨ç®ãã¦ãuASDã¨ä»ã®è¨åºçã«é¢é£ã®ãã表ç¾åã®éºä¼çéè¤ãæ¨å®ãããããã«ãStratified
Genomic SEMãé©ç¨ãã¦uASDã«è±å¯ãªéºä¼å群ãèå¥ãããæå¾ã«ãTranscriptome-Wide
SEMï¼T-SEMï¼ãå®è£
ãã¦ãuASDã¨é¢é£ããéºä¼åçºç¾ãã¿ã¼ã³ãæ¢ç´¢ããã
- çµæ
- uASDã¨ããã¤ãã®å¤é¨ãã¬ã¤ãã¨ã®æ£ã®éºä¼çç¸é¢ã観å¯ããããã®ä¸ã§ãèªç¥çã»æè²ççµæããã³å
å æ§ç²¾ç¥ç
çç¹æ§ã«é¢é£ãããã®ãé¡èã§ãã£ããStratified
Genomic SEMã§ã¯ãuASDã®éºä¼çã¯é²åçã«ä¿åãããããã»ã¹ã«é¢ä¸ããéºä¼åãçæ®ãããªãã¯ã¹ã®ãã¹ãã³ãã¼ã¯ã«ææã«è±å¯ã§ãããã¨ã示ããããT-SEMã§ã¯ãuASDã¨é¢é£ä»ããããçºç¾ãæã¤83ã®ä¸æã®éºä¼åãæããã«ãªãããã®ãã¡34ãunivariate解æã¨ã¯ç°ãªããã®ã§ãã£ãããããã®éºä¼åã¯ç®èé¢é£ã®ç
çã«éå°ã«åå¨ãã¦ããã
- çµè«
- æã ã®ç 究ã¯ã欧å·ç³»å人ããã®ãµããªã¼çµ±è¨ã«ãã£ã¦éããã¦ãããã¾ããä¸è¬çãªASD診æã«åºã¥ããã¼ã¿ã®ä½¿ç¨ã¯ãASDã«ãããèããè¨åºçç°è³ªæ§ã«è²¢ç®ããéºä¼è¦å ãç解ããè½åãå¶éãã¦ãããæã ã®çµæã¯ã解æã®ã²ãã å ¨ä½ãæ©è½ãããã³éºä¼åçºç¾ã¬ãã«ã§ADHDã¨ç¬ç«ããASDã®ä¸æã®éºä¼çåºç¤ãæããã«ãããããã«ãADHDã«å¯¾ããéåãã®å¹æã«ãã£ã¦é ããã¦ãã以åã®æ°ããé¢é£æ§ãç¹å®ããããããã®çµæã¯ãASDãçç©å¦çã«ä¸æã§ããããã»ã¹ã«ã¤ãã¦æ´å¯ãæä¾ãã¦ããã
Factors Associated with Mental Health Service Use Among Children with
ADHD from Adolescence to Early Adulthood:
- Childhood ADHD is common and linked to lifelong negative outcomes
- Little is known about factors influencing mental health service use
(MHSU) in this population
- Retrospective cohort study using data from National Longitudinal
Study of Adolescent Health
- Factors associated with MHSU included race/ethnicity, recent
physical exam, history of suicidal ideation/attempt
- Study aims to identify predictors and barriers for MHSU, inform
targeted intervention programs.
- ã¿ã¤ãã«: å°å ããªã³ãã£ãããã¢ã«ãããç²¾ç¥ç¾æ£ã®åä½µçï¼å¤æ½è¨ã³ãã¼ãç 究
- è¦ç´:
- èæ¯:
- ããªã³ãã£ãããã¢(TTM)ã¯ç²¾ç¥ç¾æ£ã®ãªã¹ã¯ãé«ãããå°å
éå£ã«ãããç 究ãä¸è¶³ãã¦ããããããããã®ãªã¹ã¯ãè©ä¾¡ããããã«ã¯ãã大è¦æ¨¡ãªç 究ãå¿
è¦ã
- æ¹æ³:
- ãã®çä¾å¯¾ç
§ç 究ã§ã¯ã2013å¹´5æ18æ¥ãã2024å¹´1æ1æ¥ã¾ã§ã®éã«è¨ºæããã18æ³ä»¥ä¸ã®å°å
TTMæ£è
ããTriNetX
global research
networkã®ç±³å½ã®ãã¼ã¿ãç¨ãã¦è©ä¾¡ããã18æ³ä»¥ä¸ã§è¨ºæãããTTMæ£è
ï¼ICD-10診æã³ã¼ãF63.3ï¼ã¨ãå¹´é½¢ãæ§å¥ã人種ãæ°æã«ãããããã³ã³ããã¼ã«æ£è
ï¼ICD-10ã³ã¼ãZ00.129ï¼ãè©ä¾¡ããããå¾åã¹ã³ã¢ãããã³ã°ã«ãããåã³ãã¼ãã«16,590人ã®æ£è
ãå¾ããããåæã¯ãADHDãè¡åé害ãããã¯é害ãå¼·è¿«æ§é害ãä¸å®é害ã解é¢æ§ãã¹ãã¬ã¹é¢é£ã身ä½å½¢å¼é害ãæ°åé害ãèªæ®ºæªéãªã©ã®å¾ç¶è¨ºæããã³ã³ããã¼ã«ã¨æ¯è¼ããã
- çµæ:
- 18æ³æªæºã®TTMæ£è
ã¯ãADHDï¼ORï¼2.002ï¼ãè¡åé害ï¼ORï¼3.668ï¼ãããã¯é害ï¼ORï¼2.247ï¼ãå¼·è¿«æ§é害ï¼ORï¼11.047ï¼ãä¸å®é害ï¼ORï¼3.583ï¼ã解é¢æ§ã»ã¹ãã¬ã¹é¢é£ã»èº«ä½å½¢å¼é害ï¼ORï¼6.179ï¼ãæ°åé害ï¼ORï¼2.476ï¼ãèªæ®ºæªéï¼ORï¼1.81ï¼ã®å¾ç¶è¨ºæã®ãªã¹ã¯ãææã«é«ãã£ããTTMæ£è
ã¯ãã¤ã³ããã¯ã¹ã¤ãã³ãå¾1å¹´ã§æãé«ãç²¾ç¥è¨ºæãªã¹ã¯ã示ããã
- çµè«:
- å°å
TTMæ£è
ã¯ãç²¾ç¥çå
±ç
ãªã¹ã¯ãé«ããç確ãªä»å
¥ã¨å
æ¬çãªç®¡çãå¿
è¦ã§ãããç®èç§å»ã¯ãè¡åããã³è¬çã±ã¢ã¸ã®ã¢ã¯ã»ã¹ãä¿é²ããæ£è
ã®ã¢ã¦ãã«ã ãåä¸ããããã¨ãã§ããã
Neonatal Survival and Outcomes following Periviable Rupture of Membranes
- ç®çï¼MHSï¼è»äºä¿å¥ã·ã¹ãã ï¼ã«ãããæ©æç ´æ°´ã«ããæ°çå ã®åå½çãæããã«ãããã¨ã
- æ¹æ³ï¼2010å¹´ãã2020å¹´ã¾ã§ã®6ã¤ã®ã¬ãã«3è»äºæ°çå éä¸æ²»ç室ï¼NICUï¼ã対象ã«ããå¾æ¹è¦çãããã³ã°ã³ãã¼ãã¬ãã¥ã¼ãè¡ããçä¾ã¯ãåºç£ç´å24æé以å ã«çºçããç ´æ°´ãå«ããå ´æãæ§å¥ãå¦å¨ é±æ°ï¼1é±é以å ï¼ãåºçæä½éï¼300ï½ä»¥å ï¼ã«ãã£ã¦1ï¼1ã«ä¸è´ããããåæ°çå ã®ãã©ãã¼ã¢ãããã¼ã¿ã¯ãä¿®æ£ããã48ãæã®å¹´é½¢ã¾ãã¯æå¾ã®å¥åº·è¨ªåã®è»ã®æ½è¨ã«ããæå¾ã®è¨é²ã¾ã§åå¾ãããã
- çµæï¼49人ã®æ°çå ãåºæºãæºããããã³ãã¼ãã®æ°çå ã®å¹³åç ´æ°´æéã¯20.7é±ã§ãå¹³åæ½ä¼æéã¯34.6æ¥ãå¹³ååºçæå¦å¨ é±æ°ã¯25.7é±ã§ãå¹³ååºçä½éã¯919gã§ãããã³ãã¼ãã®æ°çå ã¯NICUéé¢æã®çåçãã³ã³ããã¼ã«ã®77.6ï¼ ã¨æ¯è¼ãã¦75.5ï¼ ã§ãããèºé«è¡å§ãé«å¨æ³¢ã®ææ°ãªã©ã®çµ±è¨çã«ææãªçæçµæã¯ã³ãã¼ãã®æ°çå ã§é«ãã£ãããæ©ææè¡çãè³å®¤å åºè¡ãæè¡æ§è ¸å£æ»æ§ï¼NECï¼ã36é±æã®é ¸ç´ è£æ£è¬ãéé¢æã®é ¸ç´ ã«é¢ãããããªãéããè¦ãããªãã£ããé·æã®18ã48ãæé½¢æã®çµæãèªéçãè³æ§éº»çºã注ææ¬ é¥ã»å¤åæ§é害ãåæ¯ã®çºççã«ãçµ±è¨çå·®ã¯ãªãã£ãã
- çµè«ï¼MHSã«ãããã³ãã¼ãã®NICUéé¢ã®çåçã¯75.5ï¼ ã§ãããããã¯ä»¥åã«å ±åããããã®ã¨ã¯ç°ãªããããããã³ã°ãããã³ã³ããã¼ã«ã¨ãç°ãªããªãã£ããæ©æç ´æ°´å¾ã«çã¾ããä¹³å ã¯ãé«å¨æ³¢ææ°ãèºé«è¡å§ã®ç®¡çãå¯è½ãªã»ã³ã¿ã¼ã§åºç£ãã¹ãã§ãããã°ã«ã¼ãéã®é·æç¥çµçºéã«ãå·®ã¯ãªãã£ãã
Sleep problems among Asian preschool children with neurodevelopmental
disorders.
- èæ¯
- ç¡ç ã¯åä¾ã®è¡åãææ
ã®ã³ã³ããã¼ã«ãèªç¥çºéã«éè¦ãªå½¹å²ãæããã
- ç¥çµçºéé害ï¼NDDsï¼ãæã¤åä¾ã«ã¯ãç
æ°ãæããªãåä¾ãããç¡ç åé¡ãããé«ãçºççãããã
- ã¿ã¤ã®NDDsãæã¤å°±å¦åå
ç«¥ã®ç¡ç åé¡ã«é¢ããç 究ã¯å°ãªãã
- æ¹æ³
- NDDsãæã¤2ã6æ³ã®140人ã®åä¾ã¨ãåãå¹´é½¢ã®285人ã®å¥å¸¸å
ã対象ã«ãç¡ç åé¡ãæ¥æ¬èªå°±å¦åå
ç«¥ç¡ç 質å表ã®ã¿ã¤çï¼TH-JSQ-Pï¼ã使ç¨ãã¦è©ä¾¡ãæ¯è¼ããã
- NDDsã°ã«ã¼ãã®è¡ååé¡ã¯ãå
ç«¥è¡åãã§ãã¯ãªã¹ãï¼CBCLï¼ã使ç¨ãã¦è©ä¾¡ããã
- ç¡ç ã¨è¡ååé¡ã®ã¹ã³ã¢ã¯ãå¹´é½¢ãæ§å¥ãåºç¤ç¾æ£ãããã³ä½¿ç¨ãããè¬å¤ã調æ´ãã¦åæãã両ã°ã«ã¼ãéã§æ¯è¼ããã
- çµæ
- TDã°ã«ã¼ãã®48ï¼
ãNDDsã°ã«ã¼ãã®71ï¼
ãç¡ç åé¡ãæãã¦ãããã¨ãããã£ãã
- NDDsã°ã«ã¼ãã¯ãå
¨ä½çã«TH-JSQ-Pã¹ã³ã¢ãææã«é«ãã5ã¤ã®ãµãã¹ã±ã¼ã«ã«ããã¦ãé«ãã£ãã
- TH-JSQ-Pã®ã¹ã³ã¢ã¯å
é¢åããã³å¤é¢åã®è¡ååé¡ã¨ä¸ç¨åº¦ã®ç¸é¢ããããã¨ãããã£ãã
- çµè«
- 調æ»çµæãããNDDsãæã¤å°±å¦åå ç«¥ã®ç¡ç åé¡ãTDã®åä¾ãããä¸è¬çã§ãããå é¢åããã³å¤é¢åã®è¡ååé¡ã¨é¢é£ãã¦ãããã¨ã示åãããã
ãæ¯è¦ªã®å¨ç£æãã¤ç ã¨ADHDçç¶ã®ãªã¹ã¯ï¼ã·ã¹ãããã£ãã¯ã¬ãã¥ã¼ããã³ã¡ã¿åæã«ãã観å¯ã
- èæ¯:
- æ¯è¦ªã®ãã¤ç
ã¨åä¾ã®æ³¨ææ¬ å¦ã»å¤åç (ADHD)ã®çç¶ã¨ã®é¢é£ã«ã¤ãã¦ã®æµåçãªç«å¦ç証æ ãåå¨ããã
- ãã®ã·ã¹ãããã£ãã¯ã¬ãã¥ã¼ã¨ã¡ã¿åæã¯ãèåããã³ç£å¾æã«ãããæ¯è¦ªã®ãã¤ç
ã¨åä¾ã®ADHDçç¶ã¨ã®é¢ä¿ã«ã¤ãã¦ã®æ¢åã®è¨¼æ ãå
æ¬çã«çµ±åãããã¨ãç®çã¨ãã¦ããã
- æ¹æ³:
- é¢é£ããè«æãç¹å®ããããã«PubMedãMedlineãEmbaseãScopusãCINAHLãããã³PsychINFOã系統çã«æ¤ç´¢ããã
- ã©ã³ãã å¹æã¡ã¿åæã¢ãã«ãç¨ãã¦ãéè¨ãªããºæ¯ (OR) ããã³95ï¼
ä¿¡é ¼åºé (CI) ãæ¨å®ããã
- å«ã¾ããç 究å
ã®å¤åã®æ½å¨çãªè¦å ãæ¢ãããã«ãµãã°ã«ã¼ã解æãå®æ½ããã
- åºçãã¤ã¢ã¹ã¯ããã¡ã³ãã«ããããã¨Eggerã®å帰é対称æ§æ¤å®ã使ç¨ãã¦è©ä¾¡ãããã
- çµæ:
- æçµåæã«ã¯796,157ã®æ¯åãã¢ãå«ã21ã®è¦³å¯ç 究ãå«ã¾ããã
- å½ç¤¾ã®ã¡ã¿åæã§ã¯ãèåããã³ç£å¾ãã¤ç
ãçµé¨ããæ¯è¦ªã®åä¾ã«ããã¦ããããã67ï¼
(OR = 1.67, 95ï¼
CI =
1.35-2.00)ã53ï¼
(OR = 1.53, 95ï¼
CI = 1.27-1.78)ã®ADHDçç¶ã®å¢å ãªã¹ã¯ãè¦ãããã
- çµè«:
- å½ç¤¾ã®ã·ã¹ãããã£ãã¯ã¬ãã¥ã¼ã¨ã¡ã¿åæã§ã¯ãèåããã³ç£å¾ãã¤ç
ãçµé¨ããæ¯è¦ªã®åä¾ã«ããã¦ADHDçç¶ã®ãªã¹ã¯ãé«ã¾ã£ã¦ãããã¨ãç¹å®ãããã
- ãããã®çµæã¯ããªã¹ã¯ã®ããåä¾ãææ¥æã®æ©æã¹ã¯ãªã¼ãã³ã°ã¨ã¿ã¼ã²ããæåã®ä»å
¥ããã°ã©ã ã®éè¦æ§ã強調ãã¦ããã
ã¿ã¤ãã«ï¼ãããåå¿åãå©ç¨ããæ£è ã®ä½ç½®æ¤åºã«ãã褥ç¡äºé²ã¨ç®¡ç
è¦ç´ï¼
- 褥ç¡ãäºé²ã»æ²»çããããã®éè¦ãªãã¹ããã©ã¯ãã£ã¹ã¯ããªã¹ã¯ã®ããå人ãå®æçã«ä½ä½ãå¤ãããã¨ã§ããã
- ãã¼ã ã¯ããããèä¸ã®ãã¼ãã»ã«ããã®ãã¼ã¿ã使ç¨ãã¦å人ã®ãããå ã®ä½ç½®ãäºæ¸¬ããéæ¥è§¦å¼ä½ç½®æ¤åºã·ã¹ãã ãè¨è¨ããã
- å è¡ç 究ã§ã¯ãå人ã®ä½ç½®ãå·¦å´è¥ä½ãå³å´è¥ä½ãä»°è¥ä½ã¨äºæ¸¬ãããã¨ãã§ããã¨ç¤ºåãããããããé«ã精度ãå¿ è¦ã¨ãããã
- ãã®ç 究ã®ç®çã¯ãã·ã¹ãã ã®äºæ¸¬F1ã¹ã³ã¢ã使ç¨ãã¦åå è ã®ä½ç½®ãããé«ã精度ã§åé¡ãããã¨ã®å½±é¿ã調æ»ãããã¨ã§ããã
- 18人ã®åå è ã®ãã¼ã¿ãåéããåã¤ã®ãã¼ãã»ã«ã¨éª¨ç¤ã«è£ çããæ £æ§è¨æ¸¬ã¦ãããã使ç¨ãã¦ãåå è ã21ã®ä½ç½®ãåãéã®æ¨ªæé¢éª¨ç¤è§ãäºæ¸¬ããããã®åé¡å¨ãå¦ç¿ããã
- ãã³ã®ãµã¤ãºã«ãã3ã¤ã®ç°ãªãä½ç½®åé¡æ¹æ³ï¼45°ãã30°ã15°ï¼ã使ç¨ãã¦ãåé¡å¨ã®ããã©ã¼ãã³ã¹ãè©ä¾¡ããããã«ä¸äººæã交差æ¤è¨¼æ³ã使ç¨ããã
- çµæã¯ãä½ç½®ã«ãã´ãªã®ç²¾åº¦ãé«ããªãã»ã©äºæ¸¬F1ã¹ã³ã¢ãä½ä¸ãããã¨ã示ãã¦ããã
ã¿ã¤ãã«ï¼ãã¯ãªã¨ã¤ãã£ãèªèçè«:注ææ¬ å¦å¤åæ§é害ã«ãããæ¬è³ªçãªèªå·±èª¿æ´ã®ã°ã©ã¦ã³ãã£ã³ã°çè«ç 究
è¦ç´ï¼
- ç®çï¼ãã®ç 究ã®ç®çã¯ããªãæ人ã®æ³¨ææ¬ å¦å¤åæ§é害ï¼ADHDï¼æ£è ãå¤åããé害ãçµé¨ããADHDæ£è ãè¯å®çãªèªå·±èª¿æ´ã®ã¹ãã«ãçºéãããããã«ã©ã®ãããªããã»ã¹ã¨æ¦ç¥ã使ç¨ããããæããã«ãããã¨ã§ããã
- æ¹æ³ï¼2021å¹´9æãã2022å¹´2æã¾ã§ãè±å½ã®å¤§å¦ãæ人ADHDã¯ãªããã¯ãADHDãµãã¼ãã°ã«ã¼ãããã®11人ï¼å¥³æ§6人ãç·æ§5人ï¼ã®æ··åã³ã¼ãã¼ãããªã³ã©ã¤ã³ã§ã¤ã³ã¿ãã¥ã¼ãããããã¼ã¿ã¯æ§æ主義çãªã°ã©ã¦ã³ãçè«æ¹æ³è«ã«åºã¥ãã¦åæã«åéããã³åæãããã
- çµæï¼åå è ã¯ãé¢ä¸ã¨ADHDã®ç¹æ§ã®ç¹ã§ä»è ã¨ã®ã極端ãªéãã®èªèãã¨ããã«ãªã¹ãªæ³¨æãã¨ããã¤ãã¼ãã©ã¼ã«ã¹ãã¨ãã¦çµé¨ãããæèã®æ¥µç«¯ãªèªèããè¨è¿°ããããããèªå·±ã®æ ¸å¿çèªèã«å½±é¿ãä¸ããã¨è¿°ã¹ãã
ç¡éã®ãã©ãã¤ã ã使ç¨ãã¦ãçµæã¯ããããã®ç¶æ
ã®å
é¨ããã³éã§ãèªå·±å¸åãèªå·±è¶
è¶ãªã©ã®æ¦ç¥ã使ç¨ãã¦èªå·±èª¿æ´ããæªçãªè©¦ã¿ã¨ããã®å°é£ã¨ã¨ãã«ã®ã¼ã³ã¹ãã示ãã¦ããã
ã¾ããæã
ã®çµæã¯ããã®åçãªãã©ãã¤ã ã®ä¸å¿ã«ããåµé çãªèªèãã¨ããæ¦ç¥ãåå¨ãã極æ§èªèã¨ãããæ¯æããæ¬ç©ã®å
çã³ã³ãã¹ï¼AICï¼ã«ãããã®èªèã®èª¿æ´ãå®è¨¼ãã¦ããã
- çµè«ï¼ãã®è«æã¯ãADHDã¯ãªã¨ã¤ãã£ãèªèçè«ï¼CATï¼ã®å®è¨¼çãªåºç¤ãæ示ããADHDæèã¨ç°å¢ã¨ã³ã²ã¼ã¸ã¡ã³ãã®ä½é¨ãç解ããããã®æ°ããçè«ãç´¹ä»ãããå®ç¨çãªå«æãæ¢ç©¶ãããæ人ã®ADHDæ£è ã®æ¬æ¥ã®èªå·±èª¿æ´ã¹ãã«ã®ç解ã¨çºå±ã®ããã®æ çµã¿ã¨ãã¦CATã®ä½¿ç¨ãæ¨å¥¨ããã¦ããã
ã¿ã¤ãã«: ã¸ã«ã»ãã»ã©ã»ãã¥ã¬ããçå群æ£è ã«ãããéãããã¤ã§ç¤¾ä¼çã«ä¸é©åãªè¡å
è¦ç´:
- GTSã¨é¢é£ããè¡åé害ã¯ä¸è¬çã§ãããããã¯éãããã¤ã§ç¤¾ä¼çã«ä¸é©åãªè¡åï¼NOSIBsï¼ã¨ãã¦ç¾ãããã¨ãããã
- ãã®ç 究ã®ç®çã¯ãGTSãæã¤å人ã«ãããNOSIBã®é »åº¦ãçºçå¹´é½¢ãããã³ããã¯ã®éç度ã¨ã®è¨åºç¸é¢ãããã³å ±ç ç²¾ç¥é害ã®æç çãæããã«ãããã¨ã§ãã£ãã
- NOSIBã¯86人ã®GTSæ£è ã§è¦³å¯ãããæç çã¯23.6%ã§ãã£ãã
- NOSIBã¯å ¸åçã«ã¯å¹¼å°æã«ç¾ããæ£è ã®ç´ååã®ä¸ã«èµ·ãããããã¯ã®éç度ã¨å ±ç ç²¾ç¥é害ã®åå¨ã¯NOSIBã®å±éºå åã¨ãªãå¾ãã
ã¿ã¤ãã«: ADHDã®è¬ç©ãå°å ã³ãã¼ãç 究ã§ã®èº«é·ã¨ä½éã«åã¼ãæ½å¨çå½±é¿ãLIFE Child Studyã«ããã
è¦ç´:
- ç®ç: ADHDæ²»çè¬ãåä¾ãææ¥æã®èº«é·ã¨ä½éã«åã¼ãå½±é¿ã調æ»ããããã«ãLIFE Childã³ãã¼ãããã®åå è ã«ã¤ãã¦åæãè¡ã£ãã
- æ¹æ³: 48åã®ADHDè¬ç©ä½¿ç¨è ãå«ã2,115åã®åå è ã®ã¢ã³ã¹ããã¡ããªãã¯ããã³è¬ç©ãã¼ã¿ãåæãADHDè¬ç©ä½¿ç¨è ã¨é使ç¨è ã®zã¹ã³ã¢ãç¨ããç¹°ãè¿ã測å®åæ£åæãè¡ã£ãã
- çµæ: ADHDè¬ç©ä½¿ç¨è ã®ä¸ã§ãæå¾ã®è¨ªåæã«ä½éãåºæºå¤ã®25ãã¼ã»ã³ã¿ã¤ã«æªæºã®åä¾ã¨ææ¥æã®40%ããããADHDè¬ç©ä½¿ç¨è ã§ã¯èº«é·ã®zã¹ã³ã¢ãæ¸å°ããä½éãæ¸å°ããã
- çµè«: ADHDè¬ç©ä½¿ç¨è ã«ã¯èº«é·ã¨ä½éã®ä½ãå¾åãè¦ããã対å¿ããå¹´é½¢ããã³æ§å¥ã«åãããéå£ã¨æ¯è¼ãã¦ã
è«æã¿ã¤ãã«: ADHDã®éºä¼çç æ ãæããã«ããè³çµç¹ã®è»¢åã¨DNAã¡ãã«åã®ãã«ããªãã¯ã¹ç 究ã
è¦ç´:
- ADHDã¯æ£è ã®äººçå ¨ä½ã«å½±é¿ãä¸ãããã¨ãå¤ãæ ¢æ§ç²¾ç¥ç¾æ£ã§ãããéºä¼å¦ãADHDã®çºå±ã«éè¦ãªå½¹å²ãæãããã¨ãç 究ã«ãã£ã¦ç¤ºããã¦ããã
- ããããéºä¼åçºç¾ä»¥å¤ã®çç©å¦çããã»ã¹ï¼ä»£æ¿ã¹ãã©ã¤ã·ã³ã°ãDNAã¡ãã«åãªã©ï¼ã®çµç¹ç¹ç°çãªå æé¢ä¿ã«é¢ããç¥èãä¸è¶³ãã¦ããã
- ãã®è«æã§ã¯ã14種é¡ã®ç°ãªãè³çµç¹ã§ADHDã®è»¢åã¨DNAã¡ãã«åã®å æé¢ä¿ã調ã¹ãããã«ãADHDã®ã²ãã ã¯ã¤ãé¢é£ãã¼ã¿ã¨éºä¼åçºç¾ã代æ¿ã¹ãã©ã¤ã·ã³ã°ãDNAã¡ãã«åã®éçãã¬ã¤ã座ã®ãã¼ã¿ãçµ±åãããã«ããªãã¯ã¹ç 究ãè¡ãããã
- å æé¢ä¿ã¯ã4ã¤ã®ç°ãªãäºç¾¤ã¡ã³ãã«ã©ã³ãã åæ¹æ³ã使ç¨ãã¦æ¨å®ãããã
- 866ã®éºä¼åã®è¡¨ç¾ãææãªå æé¢ä¿ã示ããå°ãªãã¨ã1ã¤ã®è³çµç¹ã§ãã®ä¸ã«å«ã¾ãã¦ãããã¨ãéç¹çã«ãããããã®ä¸ã«ã¯COMMD5ãENSG00000271904ãHYAL3ãªã©ãå«ã¾ããã
- å°ãªãã¨ã1ã¤ã®14種é¡ã®ç°ãªãè³çµç¹ã§çµ±è¨çã«ææãªå æé¢ä¿ã®ãã966ã®ã¦ãã¼ã¯ãªéºä¼åãé¸å¥ãããããããã®éºä¼åã«ã¯PPP1R16AãGGT7ãTREM2ãªã©ãå«ã¾ããã
- ããã«ãä¸ä»åæãéãã¦ãDNAã¡ãã«åãéºä¼åçºç¾ã代æ¿ã¹ãã©ã¤ã·ã³ã°ããã»ã¹ãéãã¦ADHDã«å½±é¿ãä¸ããã¨æ¨æ¸¬ããã106ã®èª¿ç¯çµè·¯ãæ¨å®ãããã
- ç 究çµæã¯ãå°æ¥ã®ADHDçºå±ã®ååæ©æ§ã«é¢ããå®é¨ç 究ã«åããæéãæä¾ããADHDã®äºé²ã診æãæ²»çã®ããã®è²´éãªç¥èãæä¾ããã
Health care costs of incident ADHD in children and adolescents in
Germany - A claims data analysis within the framework of the
consortium project INTEGRATE-ADHD.
- Attention-deficit/hyperactivity disorder (ADHD) results in increased
costs for families, the healthcare system, and society.
- This study focused on children and adolescents with incident ADHD
diagnosis in Germany using data from the statutory health insurance
DAK-Gesundheit.
- A matched-control design was used to compare health care costs of
incident ADHD patients with a non-ADHD control group.
- Total health care costs for children and adolescents with ADHD in
the first year after diagnosis were significantly higher than the
control group.
- Factors such as age and comorbidity index were associated with
increased costs.
- The study emphasizes the economic burden of ADHD in children and
adolescents, highlighting the importance of social awareness,
prevention, treatment, and research efforts.
Psychometric evaluation of the Clinical Interview for Externalizing
Disorders (ILF-EXTERNAL) in an online setting - Results from the
consortium project INTEGRATE-ADHD.
- èæ¯ï¼ç 究ã¯ããªã³ã©ã¤ã³ã§ãããªãã£ãããéãã¦è¡ãããæºæ§é åã®è¨ºæé¢æ¥ILF-EXTERNALã®ADHDã»ã¯ã·ã§ã³ã®å¿çè¨éç¹æ§ã調æ»ããã
- æ¹æ³ï¼INTEGRATE-ADHDç 究ããã¸ã§ã¯ãã®ä¸ç°ã¨ãã¦ã202人ã®ADHD診æãåããåã©ãã¨ææ¥æï¼å¹³åå¹´é½¢12.87æ³ãSD
= 3.04ã女æ§28.2ï¼
ï¼ãããã¤ãã®ADHD
S3ã¬ã¤ãã©ã¤ã³ã«åºã¥ãã¦ADHDã®æç¡ãè¨åºçã«è©ä¾¡ããããILF-EXTERNALã使ç¨ãã¦ã1人ã®ä¿è·è
ã¨ã8æ³ä»¥ä¸ã®å ´åãåä¾èªèº«ãé¢æ¥ãåãããä¸æ¹ãä¿è·è
ã«ãããããã·è©ä¾¡ã¯ãã¤ãã®FBB-ADHSè©ä¾¡å°ºåº¦ã使ç¨ãã¦è¡ãããããµããµã³ãã«ï¼n
= 65ï¼ã§ã¯ãç¬ç«ãããã©ã¤ã³ãé¢æ¥å®ãILF-EXTERNALã®è¦ªé¢æ¥ã®ãããªé²ç»ãè©ä¾¡ããILF-EXTERNALã®ééããé«ããã¨ã示ããã
- çµæï¼ILF-EXTERNALã®å ¨ADHDçç¶å°ºåº¦ã¯ãè¯å¥½ããåªããå é¨æ´åæ§ï¼Î± =
0.89ã0.93ï¼ã示ãããåé¡ããã³æ¬¡å
解æã®ééããé«ããï¼Îº = 0.78ãκ = 0.81ãICC(1,1) =
0.97ã0.98ï¼ãILF-EXTERNAL親é¢æ¥ã¯FBB-ADHSï¼r = 0.79ãr =
0.85ï¼ããã³ILF-EXTERNALåä¾é¢æ¥ï¼r = 0.60ãr = 0.71ï¼ã¨é«ãç¸é¢é¢ä¿ããããã¨ãåææ¤è¨¼ãå®è¨¼ããã